<DOC>
	<DOCNO>NCT01753531</DOCNO>
	<brief_summary>The clinical performance Ultra Influenza A &amp; B Test demonstrate clinical trial prospectively collect nasal swab use identify subject infect influenza virus strain type A type B . The Ultra Influenza A &amp; B Test qualitative result compare `` Gold Standard '' viral culture Direct Fluorescent Antibody ( DFA ) confirmation technique use nasal swab collect symptomatic subject . The Ultra Influenza A &amp; B Test perform Clinical Laboratory Improvement Amendments ( CLIA ) waive site untrained intend user ( e.g . nurse , physician assistant , medical assistant , etc. ) . For viral culture test DFA confirmation testing , nasal swab specimen test perform designated reference laboratory .</brief_summary>
	<brief_title>Clinical Performance Study Ultra Influenza A &amp; B Test Using Nasal Swabs Identifying Subjects Who Are Infected With Influenza Virus Strain Type A Type B</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<criteria>The subject may age either gender . Preliminary assessment subject Investigator/designee suggestive influenza virus infection . Subject present influenzalike febrile respiratory illness define ( 1 ) presentation within last 48 hour develop subjective feeling feverish and/or temperature record clinic within last 48 hour great equal 100.5 F ( 2 ) least two follow symptom : cough , nasal congestion , rhinorrhea , sore throat , headache , myalgia . Written informed consent must obtain prior study enrollment . 1 . A subject 18 year old must willing give write informed consent must agree comply study procedure . 2 . The legal authorized representative subject age 18 must give write informed consent agree comply study procedure . Active write assent obtain child appropriate intellectual age ( defined IRB ) . The subject underwent nasal wash/aspirate part standardofcare test study visit . The subject undergoing treatment currently and/or within past 7 day study visit nasally administer influenza vaccine ( FluMist ) antiviral medication , may include limited Amantadine ( Symmetrel ) , Rimantadine ( Flumadine ) , Zanamivir ( Relenza ) , Oseltamivir ( Tamiflu ) Ribavirin . The subject currently receive receive within past thirty ( 30 ) day study visit experimental biologic , drug device , include either treatment therapy . The subject previously participate research study .</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Ultra Influenza A B</keyword>
	<keyword>Influenza Type A</keyword>
	<keyword>Influenza Type B</keyword>
	<keyword>Flu</keyword>
	<keyword>Sekisui Diagnostics</keyword>
</DOC>